Market investors and biotech venture capital firms believe that Susan Lee – chairman of Guang Li Biomedicine, and their R&D team will bring Taiwan’s biotechnology to a world-class level.
Taipei, Taiwan (Merxwire) – In recent years, the prevalence of chronic diseases has gradually made the biotechnology industry of international importance. At the 24th National Biotechnology and Medical Quality Award and SNQ National Quality Award Ceremony, Guang Li Biomedicine‘s immune cell technology product “CIK cell” wins the 2021 SNQ National Award, which has attracted attention from all walks of life. In this regard, Susan Lee, chairman of Guang Li Biomedicine, said that the increasingly mature immune cell technology would benefit more cancer patients to fight the disease. As a result, “CIK cells” won the national quality mark recognition this time, which will open a new milestone for developing immune cells.
SNQ is a rigorously scrutinized national quality certification to select outstanding companies and products. Furthermore, in line with national planning and social needs, Guang Li Biomedicine actively promotes several clinical trial programs, comprehensively enhances Taiwan’s biomedical research and patent projects, and improves the quality of medical care for the public, and thus has been recognized by the national quality certification.
According to a report by ResearchAndMarkets, a US market research institution, the global cellular immunotherapy market is expected to drop from US$2.92 billion in 2019 to US$2.74 billion in 2020, with a compound annual growth rate of -5.90%. However, the market is expected to recover and reach $5.05 billion in 2023, growing at a CAGR of 22.5%. Wall Street’s biotech venture capital experts said that Guang Li Biomedicine’s award this time represents the explosive potential of its research and development. The leading cell therapy technology will help enhance the brand value, and the potential can be expected.
In the past, the global Biotechnology Services Market lacks the constraints of strong intellectual property protection laws, making it difficult for the market to expand rapidly. However, in recent years, the medical and biotechnology industry has gradually attached importance to the value of intellectual property rights, and the number of related patents has increased, making this industry the best investment target in the eyes of venture capital companies and investors. As a result, Guang Li Biomedicine has actively obtained several domestic and foreign patented technologies, including five patents related to cell culture and storage and three patents related to blood collection and storage, to drive the overall growth of biotechnology research projects.
Guang Li Biomedicine was established in 2009. It initially developed stem cell-related technologies and services, which built a 150-square-meter exclusive cell laboratory. It was the first center in Taiwan to have both cord blood and stem cell storage services. Guang Li Biomedicine improves software and hardware technology and equipment in all aspects, improves research efficiency and quality, and becomes a biotechnology research and development indicator.
Statistics point out that the research and development market is the largest segment of the biotechnology services market, accounting for 49.1% of 2020. The Asia-Pacific region is the largest biotechnology services market, accounting for 37.5%. The data shows that biotechnology research will become a critical project in the Asian investment market. Relevant research projects will improve and enhance the quality of human life and drive overall economic growth.